Aldosterone News and Research RSS Feed - Aldosterone News and Research

Aldosterone is a steroid hormone made by the adrenal cortex (the outer layer of the adrenal gland). It helps control the balance of water and salts in the kidney by keeping sodium in and releasing potassium from the body. Too much aldosterone can cause high blood pressure and a build-up of fluid in body tissues. Aldosterone is a type of mineralocorticoid hormone.
Amgen announces phase 3 ivabradine data for treatment of chronic HF

Amgen announces phase 3 ivabradine data for treatment of chronic HF

Amgen (NASDAQ: AMGN) today announced data from the Phase 3 SHIFT (Systolic Heart failure treatment with the If inhibitor ivabradine Trial) study evaluating ivabradine in patients with chronic heart failure (HF) were presented at the 18th Annual Scientific Meeting of the Heart Failure Society of America (HFSA) in Las Vegas. [More]
Forest publishes data from pivotal Phase III Study of Investigational FDC of nebivolol and valsartan

Forest publishes data from pivotal Phase III Study of Investigational FDC of nebivolol and valsartan

Forest Laboratories, Inc. (NYSE:FRX) today announced the publication of data from its pivotal Phase III Study of an Investigational Fixed-Dose Combination (FDC) of nebivolol and valsartan in the May 30, 2014 issue of The Lancet. [More]
PARADIGM-HF trial of LCZ696 for chronic heart failure stopped early for benefit

PARADIGM-HF trial of LCZ696 for chronic heart failure stopped early for benefit

The PARADIGM-HF trial has been stopped early for a benefit to patients that was overwhelmingly statistically significant. [More]
ZS Pharma starts patient enrollment in ZS-9 Phase 3 trial for treatment of hyperkalemia

ZS Pharma starts patient enrollment in ZS-9 Phase 3 trial for treatment of hyperkalemia

ZS Pharma, a specialty pharmaceutical company developing novel treatments for kidney, cardiovascular and liver disorders, today announced that it has begun enrolling patients in ZS004, its second Phase 3 clinical trial of ZS-9, a novel investigational treatment for hyperkalemia. [More]
TOPCAT trial results of spironolactone presented at AHA Scientific Sessions

TOPCAT trial results of spironolactone presented at AHA Scientific Sessions

A late-breaking clinical trial, known as the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial, to be presented at the American Heart Association Scientific Sessions, November 18, 2013, demonstrates that spironolactone did not reduce the primary outcome of cardiovascular death, heart failure hospitalization, nor surviving a cardiac arrest in patients with heart failure and preserved ejection fraction (pump function). However, spironolactone did reduce the major burden faced by these patients-the risk of repeated hospitalizations for heart failure. [More]
Genkyotex announces initiation of GKT137831 Phase II study in patients with diabetic nephropathy

Genkyotex announces initiation of GKT137831 Phase II study in patients with diabetic nephropathy

Genkyotex, the leading developer of selective NOX enzyme inhibitors, announced today the initiation of a multinational Phase II clinical study of GKT137831 in patients with diabetic nephropathy. [More]
Insomnia poses hypertension risk

Insomnia poses hypertension risk

Insomnia may be associated with an increased risk for hypertension, research from China suggests. [More]
Simple method helps identify individuals who retain too much sodium

Simple method helps identify individuals who retain too much sodium

Getting a second urine sample and blood pressure measure as patients head out of the doctor's office appears an efficient way to identify those whose health may be in jeopardy because their bodies hold onto too much sodium, researchers report. [More]
Aliskiren does not slow progression of coronary atherosclerosis in prehypertension patients

Aliskiren does not slow progression of coronary atherosclerosis in prehypertension patients

Among patients with prehypertension and coronary artery disease, use of the renin (an enzyme secreted by the kidneys) inhibitor aliskiren, compared with placebo, did not result in improvement or slowing in the progression of coronary atherosclerosis, according to a study published by JAMA. The study is being released early online to coincide with its presentation at the European Society of Cardiology Congress 2013. [More]
AQUARIUS trial data shows Aliskiren reduced incidents of death, stroke, heart attack

AQUARIUS trial data shows Aliskiren reduced incidents of death, stroke, heart attack

Patients with clogged and hardened arteries who already have their blood pressure under control may benefit from an additional blood pressure-lowering medication, according to research from the Cleveland Clinic Coordinating Center for Clinical Research (C5Research). [More]
Renin inhibitor aliskiren not effective in slowing progression of coronary atherosclerosis

Renin inhibitor aliskiren not effective in slowing progression of coronary atherosclerosis

Among patients with prehypertension and coronary artery disease, use of the renin (an enzyme secreted by the kidneys) inhibitor aliskiren, compared with placebo, did not result in improvement or slowing in the progression of coronary atherosclerosis, according to a study published by JAMA. [More]
Study says screening heart with natriuretic peptide may reduce risk of dysfunction, heart failure

Study says screening heart with natriuretic peptide may reduce risk of dysfunction, heart failure

Among patients at risk of heart failure, collaborative care based on screening for certain levels of brain-type natriuretic peptide reduced the combined rates of left ventricular systolic dysfunction, diastolic dysfunction, and heart failure as well as emergency cardiovascular hospitalizations, according to a study in the July 3 issue of JAMA. [More]
Mount Sinai researchers present several new studies at ENDO 2013

Mount Sinai researchers present several new studies at ENDO 2013

Researchers from the Icahn School of Medicine at Mount Sinai will present several new studies at ENDO 2013, The Endocrine Society's Annual Meeting & Expo from June 15-18 in San Francisco. [More]

UCLA researchers find decrease in overall mortality rates for advanced heart failure

UCLA researchers examining outcomes for advanced heart-failure patients over the past two decades have found that, coinciding with the increased availability and use of new therapies, overall mortality has decreased and sudden cardiac death, caused by the rapid onset of severe abnormal heart rhythms, has declined. [More]
People with apple-shaped bodies more likely to develop kidney disease

People with apple-shaped bodies more likely to develop kidney disease

High blood pressure in the kidneys of people with apple-shaped bodies may be responsible for their increased risk of developing kidney disease later in life, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology. [More]

Study: Heart failure medications highly cost effective in saving lives

A UCLA study shows that heart failure medications recommended by national guidelines are highly cost effective in saving lives and may also provide savings to the health care system. [More]
Eplerenone may also reduce risk of heart failure, shows REMINDER trial

Eplerenone may also reduce risk of heart failure, shows REMINDER trial

The prescription drug eplerenone appears to reduce the risk of cardiovascular mortality and heart failure after a heart attack by more than one-third, according to research presented today at the American College of Cardiology's 62nd Annual Scientific Session. [More]
Research: Digoxin reduces hospital admission of older, acute heart failure patients

Research: Digoxin reduces hospital admission of older, acute heart failure patients

Digoxin significantly reduces the likelihood of hospital admission due to all causes among ambulatory older patients with chronic heart failure and reduced ejection fraction, according to research presented today at the American College of Cardiology's 62nd Annual Scientific Session. [More]
Aliskiren and standard therapy not associated with reduced CV death or HF rehospitalization

Aliskiren and standard therapy not associated with reduced CV death or HF rehospitalization

Among patients hospitalized for heart failure (HF) with reduced left ventricular ejection fraction (LVEF; a measure of how well the left ventricle of the heart pumps with each contraction), initiation of the medication aliskiren in addition to standard therapy did not reduce cardiovascular death or HF rehospitalization at 6 or 12 months after discharge, according to a study published online by JAMA. [More]
Benefits of diastolic function improvement in heart failure questioned

Benefits of diastolic function improvement in heart failure questioned

The importance of left ventricular diastolic function improvement in patients with heart failure with preserved ejection fraction has been questioned, after researchers found that treatment with spironolactone resulted in some functional improvements but failed to impact on patients’ exercise capacity. [More]